Biotech Startups

LENZ Therapeutics is a pharmaceutical company developing and commercializing VIZZ™, an FDA-approved aceclidine-based eye drop for treating presbyopia, a vision condition affecting over 128 million people in the US. The company is focused on providing a once-daily pharmaceutical solution to restore near vision across a broad patient population aged 45 and above.

3 investors

Leuko develops a noninvasive white blood cell monitor to track neutropenia risk in cancer patients and others undergoing treatment. The MIT spinout builds medical device hardware and AI imaging software for oncology and hematology care.

3 investors

Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization. The company serves patients with immunological disorders and rare genetic conditions.

3 investors

Lightcast provides a next-generation single-cell functional analysis platform called Envisia that enables massively parallel profiling of cell-cell interactions and biomolecule secretion at scale. The platform serves researchers and therapeutics developers studying functional biology for applications in antibody discovery, cellular therapies, and immunotherapy development.

3 investors

LimmaTech develops vaccine technologies and programs designed to combat antimicrobial-resistant pathogens and prevent severe infections. The company uses proprietary vaccine platform technology and engineered microorganisms to create vaccine solutions addressing emerging infectious diseases and antimicrobial resistance.

3 investors

Limula develops an automated, closed platform for manufacturing personalized cell and gene therapies, aiming to move production from open, manual methods to scalable automated processes. It serves cell therapy developers and manufacturers in the biotech and pharmaceutical industry, and is based in Switzerland.

3 investors

Locus Biosciences develops engineered bacteriophage therapies for treating bacterial infections and conditions in immunology, oncology, and CNS disorders. It uses a technology platform combining robotics, automated biobanking, AI-driven cocktail prediction, and synthetic biology, and operates a cGMP viral vector manufacturing facility for clinical trial material.

3 investors

LogicInk develops wearable biochemical sensors that detect environmental and personal health signals—such as UV exposure, air quality, and microbiome changes—to provide real-time wellness feedback. The platform allows users to monitor conditions impacting physical and mental health through customizable, worn sensors that integrate daily health awareness with dynamic environmental data.

3 investors

Lumira Ventures is a venture capital firm that invests in biotherapeutic and medical device companies developing innovative therapeutic solutions for patients. The firm focuses on companies creating disruptive treatments, addressing unmet medical needs, improving outcomes, and reducing healthcare costs.

3 investors

Lunaphore develops spatial biology solutions that enable scientists and clinicians to analyze tissue structure and cellular composition. The company was acquired by Bio-Techne in 2023 to expand the combined entity's capabilities in applied spatial biology.

3 investors

Lupeng Pharmaceutical develops next-generation small-molecule targeted drugs for malignant tumors and autoimmune diseases, focusing on hematologic cancer targets such as BTK, Bcl-2, and Bcl-xL, with multi-center clinical development and commercialization in international and Chinese markets. Its lead drug rocbrutinib (Lukeda) has received NMPA approval for market in China.

3 investors

Lutris Pharma develops targeted skin protection treatments for cancer patients, combining clinicians and scientists with oncology expertise. The company focuses on pharmaceutical development in the oncology and dermatology space.

3 investors

Lyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology. The company operates an integrated pipeline spanning discovery through manufacturing and clinical trials, with its own manufacturing facility in Washington.

3 investors

Lynk Pharma develops pharmaceutical products for rheumatoid arthritis and ankylosing spondylitis, with selective licensing arrangements for regional commercialization.

3 investors

Mable is a genomics-based telehealth platform that provides personalized migraine care by analyzing patients' genetic and biomarker data to inform individualized treatment plans. The company serves migraine sufferers seeking precision medicine alternatives to traditional trial-and-error medication approaches.

3 investors

Macro Oceans develops seaweed-based (kelp) feedstocks and materials as a low-carbon alternative to petroleum-based chemicals and products, building a traceable seaweed supply chain with brand, technology, and grower partners.

3 investors

Mana.bio is a biotech company that uses machine learning and high-throughput screening to design lipid nanoparticles for targeted delivery of nucleic acid therapeutics and vaccines. The company aims to unlock RNA-based treatments for genetic diseases with unmet medical needs.

3 investors

Mango Sciences works with healthcare providers in emerging markets to collect and analyze clinical patient data from underrepresented populations, building a base of real-world evidence and global health data. Its data analytics platform, paired with a patient affordability and accessibility initiative, aims to generate healthcare insights that improve patient access and care.

3 investors

Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue. Its pipeline targets challenging cancers with the goal of improving both treatment efficacy and patient experience.

3 investors

Marinatex creates plastic-free coatings and films derived from seafood processing byproducts that are designed to biodegrade safely. The company's materials serve packaging and agriculture businesses seeking alternatives to conventional plastics without requiring manufacturing process changes.

3 investors

Massive Bio operates an AI-based platform that matches cancer patients with oncology clinical trials and provides concierge support throughout the trial process. It serves patients across the U.S., Canada, Latin America, and Europe, and works with pharma and CRO customers, patient advocacy organizations, and the National Cancer Institute's network of cancer centers.

3 investors

Animate Biosciences develops peptide therapeutics that target pathological tissue remodeling, using an AI platform trained on multi-omic data from highly regenerative organisms to design novel peptides. The company applies regenerative biology and machine learning to rebuild tissue and organ systems for conditions with limited treatment options.

3 investors

Matterworks builds foundation models (its Large Spectral Model, delivered via the cloud-based Pyxis platform) that analyze biochemical omics and mass spectrometry data to make predictions for life science R&D. It serves discovery, toxicology, clinical development, and biomanufacturing teams with applications such as target discovery, toxicity prediction, and bioprocess optimization.

3 investors

Maxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs. It focuses on first-in-class and best-in-class treatments for diseases driven by ion channel and GPCR dysfunction, including pain, autoimmune and cardiovascular conditions.

3 investors